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easuring Plasma B-Type
atriuretic Peptide in Heart Failure
ood to Go in 2004?
ichard J. Rodeheffer, MD
ochester, Minnesota
Elevated plasma brain natriuretic (BNP) concentrations correlate with increased cardiac
filling pressures. Therefore, increased BNP has been proposed as a marker for asymptomatic
ventricular dysfunction, as an aid in the diagnosis of cardiac dyspnea, as an end point to assess
the efficacy of heart failure therapy, and as a prognostic marker in heart failure. An
understanding of the utility of BNP requires an appreciation of the sensitivity, specificity, and
diagnostic accuracy of BNP in each of these clinical situations. At this time, there is strong
evidence for the value of BNP in the evaluation of dyspnea of uncertain cause. Further
population studies will need to be performed to refine the application of BNP to community
cohorts and to determine its clinical value and cost-effectiveness as a screening tool in the early
diagnosis of ventricular dysfunction. To make optimal use of BNP for the assessment of heart
failure therapy and prognosis in individual patients, physicians will require additional
information on the biological variability of BNP. Studies comparing the sensitivity,
specificity, and predictive value of the available BNP and N-terminal pro-BNP assays need
to be conducted in each of these clinical settings. (J Am Coll Cardiol 2004;44:740–9)

























siscovery of the cardiac peptides in the 1980s renewed our
ppreciation of the heart as an endocrine organ (1). It also
pened a new area of cardiovascular-renal physiology, rais-
ng hope for further diagnostic and therapeutic progress in
he management of heart failure. This viewpoint will focus
n potential diagnostic utility of the natriuretic peptides,
articularly that of B-type, or brain, natriuretic peptide
BNP).
HYSIOLOGY
trial natriuretic peptide (ANP) and BNP are members of
structurally related family of peptides that are produced
nd released from cardiac myocytes (2,3). In healthy pa-
ients, ANP is produced primarily in the atria and BNP
rimarily in the ventricles. In patients with failing hearts,
eptide production increases and becomes more generalized
hroughout the myocardium (4,5). Increased cardiac filling
ressure is a potent stimulus for peptide secretion (Fig. 1)
6–9). The pro-peptide itself circulates (10). It is also
leaved into the biologically active fragment (C-BNP) and
he N-terminal pro-B-type natriuretic peptide (NT-
roBNP), both of which are measurable in plasma (10–12).
During the mid-1980s the positive correlation between
trial pressures and plasma natriuretic peptide concentration
as described, allowing peptide measurements to be con-
From the Division of Cardiovascular Diseases, Mayo Clinic and Foundation,
ochester, Minnesota. This study was funded by the Public Health Service (NIH HL
5502: to Dr. Rodeheffer), the Miami Heart Research Institute, and the Mayo
oundation. Dr. Jagat Narula acted as Guest Editor for this manuscript.
Manuscript received July 22, 2003; revised manuscript received February 23, 2004,pccepted March 2, 2004.idered as surrogates for atrial pressure measurement. In-
reased ANP release was shown to occur within minutes of
n increase in atrial pressure (8). Conversely, ANP and
NP were shown to fall as atrial pressure decreased in
esponse to heart failure treatment (13,14).
Both ANP and BNP were determined to have potent
atriuretic, diuretic, vasodilator, and antimitotic properties
hat served to counterbalance the volume retaining, vaso-
onstrictive, and ventricular remodeling effects of renin-
ngiotensin-aldosterone system activation. The natriuretic
eptides are counter-regulatory hormones that are thought
o play a role in the stabilization of circulatory function
uring the early stages of the progression of ventricular
ysfunction (15–17).
The ability of plasma ANP to distinguish asymptomatic
eft ventricular dysfunction (LVD) from normal ventricular
unction was appreciated as early as 1986 (Fig. 2) (7).
lthough initial efforts focused on ANP and N-terminal
NP as markers for ventricular dysfunction, BNP was
ventually shown to have greater sensitivity and specificity
or both systolic and diastolic dysfunction (18–20). Con-
equently, most recent studies have used BNP or NT-
roBNP.
EPTIDE AND ASSAY CONSIDERATIONS
mportant evolving issues include the choice of which
eptide to measure and the method of measuring it. During
he 1990s research laboratories developed radioimmunoas-
ays for c-terminal BNP, many using BNP antibodies
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August 18, 2004:740–9 Plasma BNP in Heart Failureont, California). Recently, a BNP assay based on the
hionogi antibody has been introduced in an automated
latform format that is applicable to hospital clinical labo-
atories (Bayer Diagnostics, Tarrytown, New Jersey). In
ddition, a point-of-care immunofluorometric assay, de-
igned to perform single BNP measurements quickly, has
een approved to aid in heart failure diagnosis (Biosite, San
iego, California). Finally, an assay for the N-terminal
omponent of BNP, NT-proBNP, has also been introduced
Roche Diagnostics, Indianapolis, Indiana). Still other ver-
ions of these assays are in development.
These assays have different characteristics, and their
elative performance has only begun to be evaluated (21,22).
n some laboratories the Shionogi assay method produces
igher BNP concentrations than the Biosite point-of-care
ssay (23). The NT-proBNP has a longer plasma half-life
han BNP, and its plasma concentrations are considerably
igher (11,12,21,22). Data from Roche Diagnostics de-
cribe an NT-proBNP assay precision of 1.8% at high
oncentrations (800 pmol/l) and 2.7% at low concentrations
20.7 pmol/l), with a lower limit of detection of 0.6 pmol/l
Abbreviations and Acronyms
ANP  atrial natriuretic peptide
AUC  area under the receiver operating curve
BNP  B-type natriuretic peptide
CHF  congestive heart failure
EF  ejection fraction
LV  left ventricular
LVD  left ventricular dysfunction
NT-proBNP  N-terminal pro-B-type natriuretic
peptide
igure 1. Schematic diagram depicting the mechanism by which cardiac
ecretion of natriuretic peptides serves to maintain intravascular volume
omeostasis. ANP  atrial natriuretic peptide; BNP  B-type natriuretic
eptide; LA  left atrium; RA  right atrium; LVEDP  left ventricular
nd-diastolic pressure; RAAS  renin-angiotensin-aldosterone system;aVEDP  right ventricular end-diastolic pressure.21–23). A report comparing the Biosite, Bayer, and Roche
ssays showed that the automated systems (Bayer for BNP
nd Roche for NT-proBNP) demonstrated the smallest
oefficient of analytic variation, just below 2% (22). The
ariation in analytic assay performance, however, was over-
helmed by substantial biologic variability (22). Among
ealthy subjects whose BNP was measured bi-weekly, the
ntra-individual variation was 33% to 59% over time, al-
hough this variation takes place largely within a low normal
ange. Among heart failure patients, the intraindividual
oefficient of variation of the Biosite BNP assay was 24%.
eart failure patients sampled every 2 h during a 24-h
eriod manifested a 77% significant serial change variation
n BNP concentration (22). The absolute magnitude of
aseline BNP and of serial variation in BNP is influenced by
he degree of circulatory decompensation. Although normal
r well-compensated heart failure patients with low BNP
oncentrations may manifest serial variation of small abso-
ute magnitude, further studies are needed to assess the
agnitude of biologic variation in poorly compensated
atients so that clinicians will be able to interpret the
ignificance of BNP change in the patients in whom it
ould be of greatest value (24,25). Although the longer
lasma half-life and lower biological variability for NT-
roBNP suggest that it could be a better marker for
etecting serial changes in BNP secretion within individu-
ls, even NT-proBNP manifests such biologic variation that
nly large changes in concentration within an individual are
ikely to be clinically significant (21,22).
Few data are available on comparative performance of
hese assays in clinical decision-making. In a study using the
iosite point-of-care BNP assay, the Roche NT-proBNP
ssay, and manually performed research laboratory assays in
cohort of 205 dyspneic patients, the commercial assays
ompared favorably with the validated research laboratory
igure 2. Plasma atrial natriuretic peptide (ANP) concentrations in normal
ubjects, asymptomatic cardiovascular (CV) disease subjects with normal or
levated pulmonary capillary wedge pressures (PCW), and symptomatic
eart failure patients (CHF) with elevated PCW pressure. (Adapted, with
ermission, from Burnett JC Jr., Kao PC, Hu DC, et al. Atrial natriuretic
eptide elevation in congestive heart failure in the human. Science
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Plasma BNP in Heart Failure August 18, 2004:740–9f the assays for dyspnea due to heart failure was 70% to
9% and was highest for the NT-proBNP assay. Sensitivity
anged from 80% to 94% and was highest for the point-of-
are Biosite assay system (21). Optimal sensitivity and
egative predictive value enhance the ability of the point-
f-care assay to rapidly exclude heart failure with a high
egree of confidence. The NT-proBNP assay, with its
lightly greater specificity and higher positive predictive
alue for heart failure diagnosis, as well as its longer plasma
alf-life, may be of greater value in other settings, such as
onitoring individual response to therapy, where optimal
pecificity is desired. Further studies are needed to deter-
ine which peptide most accurately reflects ventricular
lling pressure in a reproducible, economic, and efficient
ashion.
Appropriate reference ranges for each assay must be
stablished. In persons free of cardiovascular disease, plasma
NP and NT-proBNP increase with advancing age and are
igher in women than men (23,26). Among normal sub-
ects, higher heart rate is inversely correlated with BNP and
T-proBNP concentration (26). Adjusting the normal
ange for age and gender, rather than using a single cutoff
alue for all persons, will be important for optimal test
nterpretation. Other clinical conditions that could affect
oncentrations, such as obesity or atrial arrhythmias, also
eed to be evaluated. Although limited data are available on
NP in renal failure, current observations suggest that renal
ailure without concomitant left ventricular hypertrophy is
ot associated with elevated BNP (27,28). The association
etween BNP and left ventricular hypertrophy has also been
bserved in hypertensives (29). Further studies are needed
o evaluate the effect of renal failure on NT-proBNP.
SSESSING TEST PERFORMANCE
he literature on peptide markers has relied on Bayesian
nalysis to generate estimates of test sensitivity, specificity,
ositive and negative predictive values, and receiver operat-
ng curves. Published studies have applied these methods to
ifferent types of patient cohorts, used different assay
ystems to detect different clinical end points, and empha-
ized different threshold peptide concentrations for positive/
egative test interpretation (30).
Test performance depends on the assay used, on the
able 1. B-Type Natriuretic Peptide as a Measure of Ventricular
Study Cohort Type End Point; E
amamoto et al. (31) Echocardiography referrals;
n  466
EF  45%; 11%
aisel et al. (32) Echocardiography referrals;
n  200
EF  50% or d
ubien et al. (33) Echocardiography referrals;
n  294
Diastolic dysfun
Calculated at the B-type natriuretic peptide discriminatory value that provides best
AUC  area under the receiver operating curve; EF  ejection fraction; NPV 
pecificity.hreshold chosen to separate “normal” from “abnormal,” and en whether the prevalence of the clinical feature of interest
e.g., ejection fraction [EF] 35% or diastolic dysfunction)
s low (e.g., 10%), medium (30% to 50%), or high
60%). If the condition has a low prevalence in the study
opulation, the discriminatory test will tend to have a better
egative (“rule out”) predictive value than positive predictive
alue. Raising the discriminatory threshold for a positive
est will improve specificity and reduce sensitivity. In some
linical situations (e.g., where the disease is rapidly lethal
nd the consequences of missing the diagnosis are grave) a
ow discriminatory threshold with high sensitivity is desired
ven if it results in a greater number of false positives. In
ther situations (e.g., a research setting in which one is
rying to identify a pure cohort with a specific clinical
ondition), the discriminatory threshold may need to be
aised to optimize specificity and minimize false positives.
The fact that several variables affect sensitivity and
pecificity analyses makes it challenging to compare pub-
ished studies. In an attempt to apply a common measure of
verall test performance, this review will rely on the area
nder the receiving operating curve (AUC) as the most
ffective way to express the overall potential diagnostic value
f the test in a particular type of patient cohort. Sensitivity,
pecificity, and predictive values will be expressed at the
iscriminatory threshold value that provides the greatest
verall test accuracy, i.e., the “optimal” discriminatory value.
iscussion of specific threshold values, which vary across
tudies, will be avoided (Tables 1 to 3) (30).
OTENTIAL APPLICATIONS OF AN LVD MARKER
he BNP assay has several potential diagnostic uses: 1)
creening populations to identify asymptomatic ventricular
ysfunction; 2) assisting in the diagnosis of patients with
onspecific symptoms (e.g., dyspnea); 3) monitoring the
ffectiveness of heart failure therapy; and 4) estimating
rognosis. Each topic will be considered separately.
NP concentration and ventricular function. Three in-
estigations have attempted to establish the relationship
etween plasma BNP and ventricular function in patients
eferred for echocardiography (Table 1) (31–33). In the first
tudy, in which the end point of EF 45% was found in
1% of the cohort, the AUC was 0.79 and only the negative
redictive value (“rule out” function) of BNP was high
ction
oint Prevalence AUC SENS* SPEC* PPV* NPV*
0.79 79% 64% 21% 96%
c dysfunction; 47% 0.96 86% 98% 98% 89%
40% 0.92 74% 98% 96% 85%
l test accuracy, i.e., provides the highest combination of sensitivity and specificity.
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August 18, 2004:740–9 Plasma BNP in Heart Failurehe second study, which used a broader end point of EF
50% or Doppler evidence of diastolic dysfunction, the end
oint prevalence was 47% in the cohort; the AUC was
igher at 0.96 and was associated with good sensitivity
86%) and excellent specificity (98%) (32). The third study
ttempted to detect diastolic dysfunction only, which was
ound in 40% of the patient cohort; the AUC was 0.92, and
NP showed good specificity (98%) and positive predictive
alue (96%) (33).
In summary, studies of patient cohorts referred for
chocardiography show that high BNP concentration is
ssociated with abnormal ventricular function. It is apparent
hat BNP has good negative predictive (“rule out”) value
hen the prevalence of the end point of interest in the
ohort is low (e.g., 5% to 10%). When the end point
revalence is higher (e.g., 40% to 60%), the positive predic-
ive (“rule in”) value is improved at the expense of a




owie et al. (48) Suspected acute CHF; n  122 Confirm
avis et al. (50) Suspected acute CHF; n  52 Confirm
ogeart et al. (51) Emergency room acute dyspnea;
n  163
Confirm
orrison et al. (52) Emergency room acute dyspnea;
n  321
Confirm
aisel et al. (53) Emergency room acute dyspnea;
n  1586
Confirm
ainchbury et al. (21) Emergency room acute dyspnea;
n  205
Confirm
right et al. (49) Suspected acute CHF; n  305 Confirm
BNP B-type natriuretic peptide (BNP); †N-terminal pro BNP; ‡Calculated at the B
ombination of sensitivity and specificity.




asan et al. (20) Community volunteer;
n  3,177; age 55  10 yrs
EF  50%; 5.6
EF  40%; 2.2
LV mass 1; 4.
edfield et al. (39) Community population based;
n  1,997; age 62  11 yrs
EF  50%; 6.0






n  1,252; age 51  14 yrs


















Tertiary hospitals; n  1,050 Heart failure; 3
Calculated at the B-type natriuretic peptide discriminatory value that provides best
ASD  atrial septal defect; LV  left ventricular; M  men; MI  myocardialCHF  congestive heart failure; other abbreviations as in Tables 1 and 2.omewhat poorer negative predictive value. It should be
oted that such referral populations usually have a higher
revalence of ventricular dysfunction than would non-
eferral cohorts.
CREENING
uring the 1990s a growing appreciation of the progressive
ature of ventricular dysfunction led to an emphasis on early
etection and therapeutic intervention to attenuate the
volution to overt heart failure. Recent community studies
how that half or more of persons with ventricular systolic
nd diastolic dysfunction are asymptomatic (20,34–39).
lthough echocardiography can identify the early stages of
entricular dysfunction, its widespread application in pop-
lations is impractical and fiscally prohibitive. An inexpen-
ive blood test that would identify persons having preclinical
oint;
End Point AUC SENS‡ SPEC‡ PPV‡ NPV‡
F; 29% 0.96 NA NA NA NA
F; 62% NA 93% 90% NA NA
F; 71% 0.93 88% 87% 94% 75%
F; 42% 0.96 86% 98% 98% 83%











F; 25% 0.85 NA NA NA NA











M 0.72; W 0.56 42% 90% 30% 94%
M 0.79; W 0.85 55% 89% 18% 98%
M 0.72; W 0.57 41% 90% 32% 93%
M 0.69; W 0.70 64% 68% NA NA
M 0.90; W 0.92 90% 76% 4% 99%
; M 0.79; W 0.77 75% 69% 15% 97%
MW 0.88 76% 87% 16% 98%
l MW 0.97 90% 96% 44% 99%
MW 0.94 85% 92% NA NA
MW 0.93 NA NA NA NA
l test accuracy, i.e., provides the highest combination of sensitivity and specificity.
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Plasma BNP in Heart Failure August 18, 2004:740–9entricular dysfunction would be an attractive method of
electing persons in whom echocardiographic evaluation
ould be more cost-effective. This use of BNP is analogous
o the surveillance use of cervical pap smears or serum
rostate-specific antigen to screen for occult malignancy
37,38).
A diagnostic marker for occult ventricular dysfunction
ight be measured in all members of a community, whether
hey seek medical attention or not. Alternatively, the test
ight be applied to persons who seek medical attention for
ealth maintenance checks-ups, diagnosis of symptoms, or
reatment of a known disorder. Such self-selected clinic
ohorts are epidemiologically distinct from population-
ased community cohorts and consist of persons at higher
ikelihood of having disease.
ommunity screening. In community populations, ap-
roximately 75% of systolic dysfunction and 50% of
oderate-to-severe diastolic dysfunction in community
opulations are clinically undetected (20,34–36). Commu-
ity LVD screening, however, presents significant chal-
enges because the condition to be detected has a relatively
ow prevalence, approximately 1% to 2% for EF 40% and
% for moderate-to-severe diastolic LVD (pseudonormal or
estrictive Doppler pattern) (20,36) (Table 2).
The Framingham investigators focused on BNP to iden-
ify persons with EF 50%, EF 40%, and increased LV
ass. (20) Because of the relatively low prevalence of these
hree conditions (5.6%, 2.2%, and 4.8%, respectively) the
UCs were suboptimal, ranging from 0.56 to 0.85, and only
he negative predictive (“rule out”) values were high enough
93% to 98%) to have potential utility (Table 2). They also
etermined that the small incremental value of BNP, when
dded to other commonly available clinical data, made it
nlikely that BNP would be a useful community-screening
ool.
Data from a population-based community cohort of
,042 persons 45 years old from Olmsted County,
innesota, confirm the limited sensitivity and specificity
f BNP for both asymptomatic systolic and diastolic
entricular dysfunction (Table 2) (39). Using a likelihood
atio analysis approach, an elevated BNP predicted a
.8:1 likelihood of EF 40%. Conversely, a low BNP
ielded a 0.1:1 likelihood of EF 40%. Because of the
ow prevalence of EF 40% (1.1%), most of those with
levated BNP would actually be false positives. Indeed,
nalyses showed that if echocardiograms were obtained
nly in those with elevated BNP, 24% of the population
ould require an echocardiogram and 96% of these
chocardiograms would show EF 40% (i.e., they would
e false positives). Furthermore, the “cost” of this ap-
roach is that 10% of cases of asymptomatic EF 40%
ould be missed (i.e., they would be false negatives).
Another effort to apply BNP screening in a 1,242 person
ommunity population in Glasgow attempted to identify
ersons with EF 30%, a condition occurring in 3.2% of
heir cohort (Table 2) (40). The Glasgow investigators mmphasized the impressive 98% negative predictive value of
he test in excluding an EF30% and proposed that plasma
NP could be a useful “rule out” maneuver when applied to
ommunity populations. In a subsequent analysis, they used
linical features (symptoms, blood pressure, electrocardio-
ram [ECG]) to identify subgroups at “low” and “high” risk
f low EF (41). Models were constructed using BNP as the
creening test that would determine which persons would
roceed to echocardiography for definitive evaluation.
hen BNP concentration was added to the clinical risk
roup information, the number of echocardiograms needed
o detect one case of systolic dysfunction was reduced from
7 to 12 among high-risk patients. This suggests that a
trategy of combining clinical risk factors and BNP concen-
ration to identify candidates for echocardiography could
mprove the cost-effectiveness of case detection in commu-
ity populations.
A community-screening study in rural Japan posed a
roader clinical question, i.e., whether BNP can identify
ersons with a range of subclinical cardiovascular disorders
atrial fibrillation, previous myocardial infarction, valve dis-
ase, hypertensive ventricular hypertrophy, atrial septal de-
ect, or cor pulmonale) (Table 2) (42). In screening 1,098
ersons, 3.6% of whom had one of the heart diseases of
nterest, BNP was 90% sensitive and 96% specific for
dentifying structural heart disease. The excellent negative
redictive value of 99% was emphasized, and the AUC was
.97. The incremental value of measuring plasma BNP in
ddition to standard screening tools (physical examination,
CG, and chest radiography) was not assessed.
Again, for community screening, the diagnostic value of
NP depends greatly on the community prevalence of the
ondition, or range of conditions, one is attempting to
etect. The BNP may be more cost effective when used to
creen, as in the Japanese study, for a range of subclinical
ardiac disorders, rather than a specific level of ventricular
ystolic or diastolic dysfunction (43). Ultimately, the value
f community screening will depend upon the cost of case
dentification balanced against the savings in quality and
uration of life in those patients who receive early therapy
ased on population screening strategies. To keep the issue
n perspective, it is useful to recall that the use of serum
rostate-specific antigen in prostate cancer detection has
aken more than two decades to reach its current level of
efinement and there remains controversy about its value
44,45). Indeed, two large prospective studies are currently
nderway to assess the effectiveness of such screening on
rostate cancer outcome. Similar efforts will be necessary to
valuate the cost-effectiveness of community screening with
NP or with a combination of plasma markers and other
linical variables.
linic screening. BNP also has been used in patients who
ought participation in a multiphasic health screening pro-
ram (Table 2) (46). In this clinic setting, where the
revalence of a cardiac disease end point was 2.7% (previous
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August 18, 2004:740–9 Plasma BNP in Heart Failurease, or atrial fibrillation), BNP was more specific (92%)
han sensitive (85%), and the AUC was 0.94, suggesting
hat BNP could be useful for identifying clinic patients with
hese forms of subclinical heart disease.
A similar but somewhat more focused multicenter study
f 1,050 tertiary hospital inpatients and outpatients showed
hat BNP was capable of discriminating heart failure pa-
ients from patients without heart failure with an AUC of
.93, the test again showing better specificity than sensitiv-
ty (47). Although this number appears to be reasonably
ood test performance, it is not clear how participating
atients in this study were selected.
In summary, clinic or hospital-based screening focuses on
atient cohorts with low or moderate disease prevalence,
here BNP shows good negative predictive value. Before it
an be broadly recommended for office or hospital screen-
ng, further studies are needed to demonstrate that patient
ubgroups can be identified in whom screening with BNP is
ost-effective.
SING BNP TO ASSIST IN THE
IAGNOSIS OF CONGESTIVE HEART
AILURE (CHF) IN SYMPTOMATIC PATIENTS
common clinical dilemma is that of assigning the cause of
yspnea or exercise intolerance in persons who may have
ardiac and noncardiac (e.g., pulmonary) disease. Several
ublications have addressed the diagnostic value of BNP in
his situation (Table 3).
Among symptomatic outpatients referred by primary care
ractitioners to a cardiology clinic for possible new onset
eart failure, 29% were eventually determined to have heart
ailure. In this setting, the AUC was 0.96, suggesting that
NP may have diagnostic utility in patients suspected to
ave heart failure (Table 3) (48). In a similar primary
ractice cohort, the use of NT-proBNP improved heart
ailure diagnosis accuracy by 21%, whereas repeat clinical
valuation without knowledge of NT-proBNP improved
iagnosis by only 8% (49).
Several studies have focused on emergency room evalua-
ion of acutely dyspneic patients (50–54). The first effort to
se natriuretic peptides in the diagnosis of 52 acutely
yspneic hospitalized patients, 62% of whom were deter-
ined to have heart failure, found BNP to be superior to
NP; BNP was 93% sensitive and 90% specific for identi-
ying a cardiac cause of dyspnea; the AUC was not reported
50). Another emergency room study of 163 patients with
cute severe dyspnea in the absence of myocardial infarction,
1% of whom were found to have heart failure, showed an
UC of 0.93, a sensitivity of 88%, and specificity of 87%,
uggesting a high degree of test accuracy in this clinical
ontext (51). A similar analysis was performed in 321
mergency room patients evaluated for dyspnea, 42% of
hom were ultimately confirmed to have heart failure (52).
n this study a rapid point-of-care BNP assay distinguished
ardiac from pulmonary dyspnea with an AUC of 0.96, 86% censitivity, 98% specificity, 98% positive predictive value,
nd 83% negative predictive value. On the basis of these
romising findings, the use of BNP in emergency room
riage was expanded to a multicenter study of 1,586 dys-
neic patients, 47% of whom were found to have CHF; it
emonstrated an AUC of 0.91, 85% sensitivity, 83% spec-
ficity, 83% positive predictive value, and 85% negative
redictive value when the optimal BNP discriminatory value
as used (53). When compared with the Framingham
linical CHF diagnostic criteria, plasma BNP provided
ndependent and additive diagnostic information and im-
roved diagnostic accuracy from 73% to 84%. BNP appears
o be more useful in discriminating cardiac from noncardiac
yspnea than in distinguishing systolic from non-systolic
entricular dysfunction (54).
These studies suggesting improved emergency room
iagnostic accuracy have led to evaluation of the impact
f BNP measurement on the efficiency of patient man-
gement (55). In a controlled trial of 452 dyspneic
mergency room patients, the use of BNP in clinical
ecision-making reduced the need for hospital admission
from 85% to 75%), the need for intensive care (from 24%
o 15%), and reduced the length of hospitalization (from
1 days to 8 days).
Finally, an emergency room cohort of 205 dyspneic
atients, 34% of whom had CHF, was evaluated with
everal different BNP assay systems (21). Both the
oint-of-care BNP assay and the NT-proBNP assay had
atisfactory AUCs of 0.89. At its optimal discriminatory
oncentration, the point-of-care BNP assay showed 77%
ensitivity, 84% specificity, 71% positive predictive value,
nd 88% negative predictive value. The NT-proBNP
ssay was 80% sensitive, 87% specific, with a positive
redictive value of 76%, and a negative predictive value of
9%. These data suggest that the two assays, when used
t their “optimal” discriminatory points, are comparable
n ruling out CHF in an emergency room setting where
oughly one third of patients in fact have heart failure.
In summary, there is good evidence that BNP and
T-proBNP are useful triage tools to aid in the diagnosis of
he dyspneic patient. In this clinical setting, they have
cceptable sensitivity and negative predictive value (“rules
ut” ventricular dysfunction), both in the range of 85% to
0%. In association with the other elements of clinical
ssessment, a low BNP helps to exclude ventricular dysfunc-
ion as the cause of dyspnea.
ONITORING THERAPEUTIC RESPONSE
ecause BNP levels correlate with atrial and ventricular
lling pressures, it is reasonable to ask whether changes in
NP are able to mirror the effectiveness of therapies
esigned to reduce filling pressures. In patients being
reated for acutely decompensated heart failure, BNP con-
entration decreases in parallel with the fall in pulmonary
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Plasma BNP in Heart Failure August 18, 2004:740–9owever, few data have yet been published on the effec-
iveness of BNP “guided” therapy.
A study of 69 hospitalized heart failure patients reported
hat BNP-guided management reduced the number of
ubsequent cardiovascular events by 65% during 9.5 months
f follow-up (56). Although this is provocative and prom-
sing, confirmatory data are needed.
A single study of 152 patients with diastolic dysfunction
ue to amyloidosis indicated that plasma NT-proBNP was
sensitive indicator of the extent of cardiac amyloid
nvolvement. The changes in NT-proBNP concentration
orrelated with changes in clinical symptoms (57).
The plasma natriuretic peptide concentration also may be
f value in estimating the potential benefit of specific
herapeutic interventions. In patients with ischemic cardio-
yopathy, elevation of BNP without marked activation of
orepinephrine identified a group who had the best re-
ponse to beta-blockade with carvedilol (58). In a study of
cute digitalis administration, patients with the highest
lasma ANP concentration had the most impressive hemo-
ynamic improvement from digitalis (14).
In summary, BNP assays are able to track therapeutic
esponse in cohorts of patients where one is evaluating
hanges in group mean BNP concentrations. Therefore,
NP may be a useful end point in clinical trials. Early
linical experience applying these findings to individual
atients, however, suggests that the intra-individual biologic
ariation of BNP may make interpretation of serial mea-
urements difficult (22). The mean changes in BNP re-
orted in groups of patients undergoing a therapeutic
ntervention mask the considerable biologic variance in
NP concentration observed within individuals. To be able
o confidently interpret BNP changes within an individual,
he magnitude of change must be large, and just how large
as not been determined.
STIMATING PROGNOSIS
any factors have been shown to have prognostic value in
eart failure. Demographic variables, symptom severity,
hysical signs, echocardiographic, roentgenographic and
cintigraphic measurements, hemodynamic parameters, ex-
rcise capacity, neurohumoral perturbations, and genetic
olymorphisms have been shown to be associated with poor
utcome. Because these variables are all covariates of poor
ardiac performance, it is not surprising that natriuretic
eptides also have prognostic value.
An early effort to use a cardiac peptide in a cohort at high
isk for developing new heart failure was the measurement
f ANP in 310 elderly (mean age, 90 years) nursing-home
esidents (59). In this group, an elevated ANP was 85%
ensitive and 66% specific for the development of a subse-
uent heart failure episode during one year of follow-up.
gain, the positive predictive value was low at 30%, whereas
he negative predictive value was high at 96%. A Framing-
am community study has further shown that after adjust- tent for cardiovascular risk factors, increased BNP is
trongly associated with increased risk of heart failure, atrial
brillation, and death (Fig. 3) (60).
Elevated ANP and BNP have been shown to be predic-
ive of poor long-term survival in outpatients with estab-
ished heart failure (61–64). Also of interest is the observa-
ion that BNP was the only predictor of sudden cardiac
eath in a cohort of 452 heart failure patients followed for
n average of 1.6 years (65). A further refinement of this
bservation is that of combining plasma BNP and pro-
onged rate-corrected QT-interval in heart failure patients;
n those with elevated BNP, rate-corrected QT-interval was
strong and independent predictor of total mortality, as
ell as sudden death mortality (66).
Among patients with unstable angina and myocardial
nfarction, BNP has been shown to have prognostic value,
ncremental to troponin concentration, for subsequent car-
iac events or death (67–72). When a panel of neurohor-
ones (including BNP and catecholamines) was measured
ne to four days after acute infarction, BNP was the only
ndependent predictor of late EF 40% and was the most
owerful predictor of death within four months after infarc-
ion (71). In 2,525 acute myocardial infarction patients, the
agnitude of BNP elevation correlated with mortality,
eart failure, and recurrent infarction at both 30 days and 10
onths (68). Studies using NT-proBNP have shown it to
ave similar independent predictive value for adverse
ostinfarction clinical outcomes (69,72). A strategy of
ombining EF and BNP (or NT-proBNP) improved risk
tratification beyond using either alone (72).
A further refinement of the use of BNP to estimate
rognosis is the evaluation of a change in BNP to predict
linical outcomes. In acutely decompensated hospitalized
eart failure patients, a decrease in BNP during treatment
as associated with fewer adverse events after discharge
73). Conversely, in 4,300 outpatients with chronic heart
ailure, those with the greatest increase in BNP despite
igure 3. Cumulative incidence of heart failure according to plasma B-type
atriuretic peptide level at baseline in Framingham participants. (Adapted,
ith permission from Wang TJ, Larson MG, Levy D, et al. Plasma
atriuretic peptide levels and the risk of cardiovascular events and death.
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August 18, 2004:740–9 Plasma BNP in Heart FailureNatriuretic peptides also have been used to estimate
rognosis in other cardiovascular conditions. Two studies of
cute pulmonary embolism show that patients with low
lasma BNP or NT-proBNP concentrations had an un-
omplicated clinical course when compared with those with
igh NT-proBNP (75,76). These findings are physiologi-
ally consistent with our understanding of the effect on
brupt and dramatic increase in right ventricular afterload
ould have on the stimuli for BNP release. In the setting of
alve disease plasma, BNP increases with the severity of
ortic stenosis and mitral regurgitation (77,78). Again, these
onditions, as they advance, result in increased atrial pres-
ure and distention.
In summary, plasma BNP concentration is a carrier of
ignificant prognostic information. How much it adds to
ther routinely collected clinical information needs to be the
ocus of further study.
UTURE RESEARCH
rom the discussion outlined above, several fertile fields for
uture investigation are evident. To use BNP to screen
opulations for asymptomatic ventricular dysfunction, it will
e important to demonstrate that BNP can be used to
rovide a cost-effective strategy for selecting persons in
hom more definitive (and expensive) evaluation with
chocardiography is warranted. This will require estimation
f the cost per case identified and the savings in quality and
uration of life that can be gained by early diagnosis and
reatment of ventricular dysfunction. It may be that other
lasma markers or combinations of markers, or plasma
arkers combined with other clinical variables, will be more
iscriminatory.
Because natriuretic peptide concentrations are affected by
actors that impact cardiac filling pressure, their concentra-
ion in an individual patient may fluctuate over minutes to
ours depending on posture, the timing of medication
oses, recent sodium and water intake, and changes in
entricular afterload. The data on biological variability of
NP and NT-proBNP discussed above suggest that these
ests may be helpful in studying the impact of therapy in
arge cohorts of patients (e.g., in clinical trials) but that it
ill be more difficult to apply them to the management of
ndividual patients. For a plasma marker to be more useful
n the management of individual patients, it would be
esirable to have assays that reflect integrated “average”
eptide concentrations over time. The analogy is that of
easuring spot serum glucose versus hemoglobin A1c to
onitor glycemic control in an individual diabetic patient.
lthough NT-proBNP appears to have a slight advantage
n this regard, the search for better peptide markers should
ontinue.
Long-term studies of the efficacy of peptide measurement
ill need to include direct comparison of different assay
ethods. Further studies also will be needed to isolateonfounding variables that could affect BNP concentration,uch as renal dysfunction, obesity, cor pulmonale, atrial
brillation, or concomitant medications. Factors that
hange either secretion or clearance of the BNP peptide may
hange the plasma concentration and complicate its
nterpretation.
ONCLUSIONS
he introduction of the natriuretic peptides as diagnostic
ools in ventricular dysfunction has given rise to high
xpectations as to their accuracy and clinical value. It should
e noted, however, that the diagnostic utility of BNP is still
work in progress. At this time, it is reasonable to adopt
lasma BNP as an aid in the diagnosis of dyspneic patients
n whom the cause is uncertain. It also is appropriate to use
NP as a prognostic marker for unstable angina or in
atients after myocardial infarction. At this time, the
elative merits of the available assays for BNP and NT-
roBNP, the value of BNP in the screening of asymptom-
tic patients, and value of BNP in monitoring therapy are
mportant areas for continuing investigation.
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